Chongqing Precision Biotechnology Submits IPO Prospectus Following NMPA Approval of Puzolcabtagene Autoleucel for Relapsed/Refractory B-ALL in Pediatric and Young Adult Patients

Recently, the National Medical Products Administration has granted conditional approval through the priority review and approval process.Chongqing Precision Biotech Co., Ltd. announced the market launch of its Prgio-loncell Injection (brand name: Pulidekai)., for the treatment of refractory or relapsed (relapse after 12 months of initial remission requires salvage chemotherapy) CD19-positive patients aged 3 to 21.Patients with Acute B Lymphoblastic Leukemia. The listing of this variety provides a new treatment option for relevant patients.